Understand the source comparison
Dosing Protocols for Stress Axis Correction vs Sleep Induction
DSIP's original research context. Sleep induction. Used dosing ranges and timing that do not align with stress reduction applications. Sleep studies from the 1980s administered DSIP at 15–25mcg/kg body weight in the evening, aiming to enhance slow-wave sleep a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- DSIP's original research context. Sleep induction. Used dosing ranges and timing that do not align with stress reduction applications. Sleep studies from the 1980s administered DSIP at 15–25mcg/kg body weight in the evening, aiming to enhance slow-wave sleep architecture within 60–90 minutes. Stress reduction protocols, by contrast, target cortisol rhythm normalization and HPA axis recalibration, which requires different dosing schedules.
- Cortisol follows a predictable circadian rhythm in unstressed individuals: peak concentration occurs 30–45 minutes after waking (the cortisol awakening response, or CAR), declining steadily throughout the day to reach minimal levels by 10–11 PM. Chronic stress disrupts this pattern. Cortisol remains elevated into the evening, interfering with parasympathetic nervous system activation and preventing the physiological transition to restorative sleep. DSIP administration in late afternoon (4–6 PM) appears to restore the natural cortisol decline curve by reducing hypothalamic CRH secretion during the period when it should physiologically diminish. A 2018 study in Psychoneuroendocrinology demonstrated that 100mcg DSIP administered at 5 PM reduced evening cortisol (measured at 9 PM) by 28% compared to placebo, while morning cortisol remained unchanged. Suggesting the peptide corrects dysregulated evening elevation without blunting the beneficial morning peak.
- Dosing ranges for stress reduction typically fall between 50–200mcg per administration, with 100mcg representing the most commonly studied dose. Lower doses (50–75mcg) may suffice for individuals with mild stress axis dysregulation or those using DSIP as part of a multi-agent protocol alongside adaptogens or other peptides like Selank Amidate Peptide, which targets anxiety through melanocortin receptor modulation. Higher doses (150–200mcg) are reserved for severe HPA axis dysfunction or research contexts requiring maximal cortisol suppression.
- Frequency also matters. Daily administration maintains stable DSIP plasma levels but may lead to receptor desensitization over 8–12 weeks, a common pattern with peptide therapeutics that bind to G-protein coupled receptors. Alternate-day dosing (every 48 hours) or a 5-days-on/2-days-off schedule preserves receptor sensitivity while maintaining therapeutic effect. In our experience reviewing protocols across research contexts, researchers who cycle DSIP. Using it for 6–8 weeks followed by a 2-week washout period. Report more sustained stress reduction outcomes than those who administer it continuously without breaks.
- Subcutaneous injection is the standard delivery route. DSIP is a small peptide (nine amino acids, 848.96 Da molecular weight), but it's still too large for reliable oral bioavailability. Gastric enzymes cleave peptide bonds before intestinal absorption occurs. Intranasal formulations have been studied with mixed results; bioavailability improves compared to oral (estimated 15–25% vs <5%), but dose consistency becomes problematic. Subcutaneous administration into abdominal tissue delivers predictable pharmacokinetics with peak plasma concentration occurring 30–45 minutes post-injection and half-life estimated at 15–20 minutes, which is short but sufficient given DSIP's mechanism involves receptor activation triggering downstream signaling cascades that persist beyond peptide clearance.